23.05
1.10%
0.365
Precedente Chiudi:
$22.69
Aprire:
$22.78
Volume 24 ore:
43,363
Relative Volume:
0.08
Capitalizzazione di mercato:
$1.56B
Reddito:
$71.30M
Utile/perdita netta:
$-354.80M
Rapporto P/E:
-4.1243
EPS:
-5.59
Flusso di cassa netto:
$-356.00M
1 W Prestazione:
-7.95%
1M Prestazione:
-10.95%
6M Prestazione:
-33.80%
1 anno Prestazione:
+10.29%
Arvinas Inc Stock (ARVN) Company Profile
Nome
Arvinas Inc
Settore
Industria
Telefono
203-535-1456
Indirizzo
395 WINCHESTER AVE, NEW HAVEN, CT
Confronta ARVN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
ARVN | 23.01 | 1.56B | 71.30M | -354.80M | -356.00M | -5.59 |
VRTX | 446.42 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 739.53 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 587.24 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.48 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-02-14 | Downgrade | Citigroup | Buy → Neutral |
2024-02-01 | Iniziato | Goldman | Buy |
2023-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2023-12-06 | Aggiornamento | Jefferies | Hold → Buy |
2023-11-20 | Aggiornamento | Guggenheim | Neutral → Buy |
2023-10-23 | Aggiornamento | Wedbush | Neutral → Outperform |
2023-06-26 | Ripresa | Oppenheimer | Outperform |
2023-01-12 | Downgrade | Guggenheim | Buy → Neutral |
2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2022-09-09 | Iniziato | Barclays | Overweight |
2022-06-21 | Iniziato | Jefferies | Hold |
2022-05-09 | Downgrade | Wedbush | Outperform → Neutral |
2022-04-28 | Iniziato | Credit Suisse | Outperform |
2022-04-06 | Iniziato | Morgan Stanley | Equal-Weight |
2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
2022-02-10 | Iniziato | Wells Fargo | Overweight |
2022-01-19 | Iniziato | Goldman | Buy |
2021-12-07 | Iniziato | Cowen | Outperform |
2021-10-14 | Iniziato | SVB Leerink | Outperform |
2021-09-30 | Iniziato | Stifel | Buy |
2021-09-09 | Iniziato | BofA Securities | Buy |
2021-05-21 | Iniziato | UBS | Buy |
2021-04-21 | Iniziato | Truist | Buy |
2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
2020-12-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
2020-06-01 | Aggiornamento | Citigroup | Neutral → Buy |
2020-05-12 | Iniziato | Oppenheimer | Perform |
2019-12-19 | Iniziato | H.C. Wainwright | Buy |
2019-11-25 | Iniziato | Guggenheim | Buy |
2019-10-24 | Aggiornamento | Goldman | Neutral → Buy |
2019-09-25 | Iniziato | Wedbush | Outperform |
2019-09-12 | Iniziato | BMO Capital Markets | Outperform |
2019-08-06 | Iniziato | Cantor Fitzgerald | Overweight |
2019-06-05 | Downgrade | Citigroup | Buy → Neutral |
2019-04-12 | Iniziato | Evercore ISI | Outperform |
2018-10-22 | Iniziato | Citigroup | Buy |
2018-10-22 | Iniziato | Goldman | Neutral |
2018-10-22 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Arvinas Inc Borsa (ARVN) Ultime notizie
Arvinas stock remains a Top Pick despite slight reduction in price target, says BMO - Investing.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out - AccessWire
Unveiling 4 Analyst Insights On Arvinas - Benzinga
Arvinas shares target cut to $62 on delayed trial data - Investing.com
Arvinas reports delay in breast cancer trial results - Investing.com India
Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode - Insider Monkey
Pfizer, Arvinas delay late-stage trial for breast cancer therapy - Seeking Alpha
Stephens Begins Coverage on Arvinas (NASDAQ:ARVN) - MarketBeat
Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Drops By 5.6% - MarketBeat
Stephens & Co. Initiates Coverage of Arvinas (ARVN) with Overweight Recommendation - MSN
RTW INVESTMENTS, LP Adjusts Stake in Arvinas Inc - GuruFocus.com
Arvinas chief accounting officer David Loomis sells $10,300 in stock By Investing.com - Investing.com Australia
Arvinas chief accounting officer David Loomis sells $10,300 in stock - Investing.com
How the (ARVN) price action is used to our Advantage - Stock Traders Daily
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Receives $56.92 Consensus Target Price from Analysts - MarketBeat
Arvinas (ARVN) Stock Price, News & Analysis - MarketBeat
Arvinas's SWOT analysis: biotech stock poised for pivotal trial results - Investing.com India
Arvinas's SWOT analysis: biotech stock poised for pivotal trial results By Investing.com - Investing.com Canada
Allspring Global Investments Holdings LLC Has $182,000 Stake in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Arvinas to Participate in Upcoming Investor Conferences - GlobeNewswire
Arvinas (NASDAQ:ARVN) Receives Buy Rating from HC Wainwright - Defense World
FY2024 EPS Estimates for Arvinas Reduced by Leerink Partnrs - MarketBeat
Wedbush Issues Pessimistic Estimate for Arvinas Earnings - Defense World
FY2024 EPS Estimates for Arvinas Cut by Leerink Partnrs - Defense World
Arvinas (NASDAQ:ARVN) Price Target Lowered to $40.00 at Oppenheimer - Defense World
Arvinas Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Oppenheimer cuts Arvinas shares price target to $40 ahead of TACTIVE-U trial - Investing.com
Arvinas' (ARVN) Buy Rating Reiterated at HC Wainwright - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Q3 2024 Earnings Call Transcript - Insider Monkey
Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates - MSN
Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Reve - GuruFocus.com
Assenagon Asset Management S.A. Invests $3.44 Million in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ... - Yahoo Finance
Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ... By GuruFocus - Investing.com Canada
Arvinas Reports Progress in Q3 2024 Financials and Trials - TipRanks
Arvinas Inc (ARVN) Q3 2024 Earnings: Revenue Soars to $102.4M, B - GuruFocus.com
Arvinas (NASDAQ:ARVN) Trading 4.3% HigherTime to Buy? - MarketBeat
Arvinas earnings beat by $0.16, revenue topped estimates - Investing.com Canada
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Arvinas, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Arvinas Inc (ARVN) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Arvinas, Inc. (NASDAQ:ARVN) Short Interest Down 12.7% in October - MarketBeat
We're Hopeful That Arvinas (NASDAQ:ARVN) Will Use Its Cash Wisely - Yahoo Finance
Arvinas (ARVN): A Small-Cap Biotech with High Growth Potential - Insider Monkey
Arvinas (ARVN) to Release Earnings on Wednesday - MarketBeat
8 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day - ForexTV.com
SG Americas Securities LLC Sells 76,236 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas Inc Azioni (ARVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arvinas Inc Azioni (ARVN) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Houston John G | President and CEO |
Feb 23 '24 |
Sale |
47.05 |
5,196 |
244,472 |
1,036,681 |
Cassidy Sean A | Chief Financial Officer |
Feb 23 '24 |
Sale |
47.05 |
1,702 |
80,079 |
181,916 |
Peck Ronald | Chief Medical Officer |
Feb 23 '24 |
Sale |
47.05 |
1,699 |
79,938 |
67,516 |
Taylor Ian | Chief Scientific Officer |
Feb 23 '24 |
Sale |
47.05 |
1,701 |
80,032 |
147,522 |
Taylor Ian | Chief Scientific Officer |
Jan 04 '24 |
Option Exercise |
16.00 |
8,252 |
132,032 |
109,973 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):